Company intelligence / Profile preview

Vera Therapeutics

Brisbane, California, United Statesveratx.com ↗

Ownership: Public · VERA
Employees: ~125
Development stage: Phase 3

Overview

Vera’s lead candidate atacicept demonstrated sustained eGFR stabilization through a Phase 2b trial in IgAN. The pivotal Phase 3 ORIGIN trial was initiated in June 2023. MAU868 completed a Phase 2 trial showing clinically meaningful reductions in BK viral activity with good tolerability. VT‑109 was recently licensed from Stanford University as a next-generation BAFF/APRIL dual-inhibitor for B cell mediated diseases.[2][6][7]

Therapeutic areas: ImmunologyInfectious DiseasesNephrology
Modalities: Fusion proteins (e.g., TACI-Fc fusion protein)[2][5]Monoclonal antibodies[2][5]
Industry: Biotech

Drug pipeline

3 assets

atacicept

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Exclusive license agreement with Stanford University for VT‑109 technology[7]Collaborations with CROs and CMOs for clinical trials and manufacturing support[6]

Financials

Market cap: $2.5B
Total revenue: $0
Enterprise value: $2.1B

Beyond the preview

Go deeper on Vera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vera Therapeutics.

Explore the full profile